0000000000471390

AUTHOR

Axel Hegele

showing 4 related works from this author

The Immune Checkpoint Molecule CD200 Is Associated with Tumor Grading and Metastasis in Bladder Cancer.

2018

BACKGROUND We examined the expression of CD200, a ligand of immune tolerance, in transitional cell carcinoma of the human bladder (TCC). MATERIALS AND METHODS CD200 was analyzed by immunohistochemistry (IHC) in 90 patients with suspected TCC lesions of the bladder. Expression of CD200 was exemplarily validated by quantitative reverse transcription polymerase chain reaction and western blot analysis. RESULTS CD200 was detectable at mRNA and protein levels in TCC homogenate and TCC cell lines (T24, UMUC3). TCC tissues showed significantly higher CD200 expression (p<0.005) than normal bladder tissues. CD200 signals were also higher in metastasized compared to localized TCC (p<0.05). CD200 was …

MaleCancer Researchmedicine.medical_treatmenturologic and male genital diseasesMetastasis03 medical and health sciences0302 clinical medicineWestern blotAntigens CDmedicineBiomarkers TumorHumansRNA MessengerRNA NeoplasmNeoplasm MetastasisneoplasmsAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellBladder cancermedicine.diagnostic_testbusiness.industryCell DifferentiationGeneral MedicineImmunotherapymedicine.diseasefemale genital diseases and pregnancy complicationsImmune checkpointNeoplasm ProteinsReverse transcription polymerase chain reactionTransitional cell carcinomaOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleTumor EscapeNeoplasm Gradingbusiness030215 immunologyAnticancer research
researchProduct

mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.

2018

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. Patients and Methods: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. Results: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months wit…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSingle CenterGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorTargeted therapylaw.invention03 medical and health sciences0302 clinical medicineRisk groupsRandomized controlled trialRenal cell carcinomalawRisk FactorsInternal medicineGermanymedicineOverall survivalHumansMolecular Targeted TherapyNeoplasm MetastasisSurvival rateCarcinoma Renal CellProtein Kinase InhibitorsAgedRandomized Controlled Trials as TopicRetrospective StudiesPharmacologybusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisFemalebusinessResearch ArticleIn vivo (Athens, Greece)
researchProduct

Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series

2019

Background. Vinflunine (VFL) is approved in Europe as second-line treatment of metastatic urothelial cancer after failure of platinum-containing therapy. We performed a systematic review and meta-analysis of real-world data (RWD) to assess utilization, efficacy and safety of VFL. \ud \ud Methods. We performed a MEDLINE search for the period of 1/1/2000-31/8/2017. Full-length articles providing post-marketing RWD on VFL in patients failing previous chemotherapy were eligible. Interventional clinical trials were excluded. \ud \ud Results: Ten studies with 797 patients were identified. According to pooled REs analysis, overall response rate was 19%, most frequent, all-grade toxicities were fat…

Male0301 basic medicineOncologyUrologic Neoplasmsmedicine.medical_specialtyVomitingNauseamedicine.medical_treatmentMEDLINEPlatinum CompoundsNeutropeniaVinblastine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineNeoplasm MetastasisFatigueAgedChemotherapyVinfluninebusiness.industryNauseaHematologyMiddle Agedmedicine.diseaseEuropeClinical trialTreatment Outcome030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisMeta-analysisVomitingFemalemedicine.symptombusinessConstipationCritical Reviews in Oncology/Hematology
researchProduct

&lt;p&gt;Chemotherapy of Locally Advanced or Metastatic Urothelial Cell Carcinoma: Monocentric Real-Life Data&lt;/p&gt;

2020

Background/Aim Up to 30% of all patients will present with an advanced or a metastatic stage (mUCC) at the moment of the initial diagnosis of urothelial cell carcinoma of the bladder (UCC). We investigated the numbers, the efficacy and toxicity of different chemotherapies for mUCC in daily practice and "real-life" conditions and evaluated them substance-specifically. Patients and Methods All patients with a mUCC, who were treated between January 1, 2006 and October 31, 2016 at the Department of Urology and Pediatric Urology at University Hospital Marburg (Germany), were retrospectively analyzed. We set the focus on demographic and tumor-specific data as well as on effectiveness, therapy seq…

0301 basic medicineCisplatinOncologyChemotherapymedicine.medical_specialtyBladder cancerMetastatic Urothelial Carcinomabusiness.industrymedicine.medical_treatmentmedicine.diseaseGemcitabinePediatric urology03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyUrothelial cell carcinoma030220 oncology & carcinogenesisInternal medicinemedicineStage (cooking)businessmedicine.drugCancer Management and Research
researchProduct